UHealth - University of Miami Health System

Seung-Uon Shin, PhD

General Information

Seung-Uon  Shin, PhD

Contact

  • .(JavaScript must be enabled to view this email address)

Languages

  • English

Roles

  • Research Associate Professor
  • Research Associate Professor, Rosenblatt Laboratory

CV

Education

1990 Postdoctoral Fellow
University of California, Cancer Research Institute
1988 Postdoctoral Fellow
Columbia University, Cancer Research Institute
1987 Ph.D.
Albert Einstein College of Medicne
1978 M.S.
Seoul National University
1976 B.S.
Kyung-Hee University

Publications

  • Zhang Y, Eliav Y, Shin SU, Schreiber TH, Podack ER, Tadmor T, Rosenblatt JD. B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion. Cancer Immunol Immunother. 62(1):87-99, 2013.
  • Choe SC, Zhao G, Zhao Z, Rosenblatt JD, Cho HM, Shin SU, Johnson NF. Model for in vivo progression of tumors based on co-evolving cell population and vasculature. Sci Rep. 1:31, 2011.
  • Shin SU, Cho HM, Merchan JR, Zhang J, Kovacs K, Jing Y, Ramakrishnan S, Rosenblatt JD. Targeted delivery of an antibody-mutant human endostatin fusion protein results in enhanced anti-tumor efficacy. Mol Cancer Ther. 10(4):603-14, 2011
  • Cho HM, Rosenblatt JD, Tolba K, Shin SJ, Shin DS, Calfa C, Zhang Y, Shin SU. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response. Cancer Res. 70(24):10121-30, 2010.
  • Nechushtan H, Pham D, Morgensztern D, Yi K, Shin S-U, Federoff H, Bowers WJ, Tolba K, Rosenblatt JD. Augmentation of antitumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction. Cancer Immunol Immunotherapy. 57(5):663-75, 2008.
  • Calfa CI, Rosenblatt JD, Cho H-M, Webster WA, Shin S-U. Antibodies and antibody-fusion proteins as anti-angiogenic, anti-tumor agents. Update on Cancer Therapeutics 1(2):159-73, 2006.
  • Cho, H.-M., Rosenblatt, J. D., Kang, Y. S., Iruela-Arispe, M. L., Morrison, S. L., Penichet, M. L., Kwon, Y. G., Kim, T. W., Webster, K. A., Nechustan, H., Shin, S.-U. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein. Mol Cancer Ther. 4(6):956-67, 2005
  • Shah, S., Divekar, A. A., Hilchey, S. P., Cho, H.-M., Newman, C. L., Shin, S.-U., Nechustan, H., Challita-Eid, P. M., Segal, B. M., Yi, K. H. and Joseph D. Rosenblatt, D. J. Increased rejection of primary tumors in mice lacking B cells: Inhibition of anti-tumor CTL and T(H)1 cytokine responses by B cells. Int J Cancer. 117(4):574-586, 2005.
  • Lee, Y. J., Kim, D. H., Chung, Y., Shin, S.-U. and Kang, C. Y. Comparison of the antitumor efficacies of Her-2/neu DNA vaccines inducing contrasting IgG immunity but comparable CTL activity in mice. Vaccine 21(5-6):521-31, 2003.
  • Kim, K. M., Shin, E. Y., Moon, J. H., Heo, T. H., Lee, J. Y., Chung, Y., Lee, Y. J., Cho, H. M., Shin, S.-U., Kang C.Y. Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen. Int. J. Cancer, 102(4):428-34, 2002.
  • Rosenblatt, J. D., Shin, S.-U., Nechustan, H., Yi, K. H., Tolba, K. Potential role of chemokines in immune therapy of cancer. Isr Med Assoc J. 4(11):1054-9, 2002.
  • Ng, P.P., Dela Cruz, J.S., Sorour, D.N., Stinebaugh, J.M., Shin, S.-U., Shin, D.S., Morrison, S.L., Penichet, M.L. An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc Natl Acad Sci U S A. 99(16):10706-11, 2002.
  • Penichet, M. L., Cruz, J., Shin, S.-U. and Morrison, S. L. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Human Antibodies, 10(1):43-9, 2001
  • Penichet, M. L., Kang, Y.-S, Pardridge, W. M., Morrison, S. L. and Shin, S.-U. An antibody-avidin fusion protein specific for transferrin receptor serves as a delivery vehicle for effective brain targeting: Initial applications in antisense AIDS drug delivery to the brain. J. Immunol., 1999, 163:4421-4426.
  • Cho, H. M., Shin, S.-U. and Kim, T. Y. Comparison of surface and core peptide fraction from Apo B-100 of human LDL (low density lipoprotein). J. Food Sci. Nutr. 1999, 4(2):145-151.
  • Penichet, M. L., Challita, P.-M., Shin, S.-U., Sampogna, S. L., Rosenblatt, J. D. and Morrison, S. L. In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. Lab. Anim. Sci., 1999, 49(2):179-88.
  • Cho, H. M., Kim, H. J., Cho, M.-Y. and Shin, S.-U. Anti-cancer efficacy of anti-CEA IgG3 in a syngeneic carcinoembryonic antigen tumor model. Korean J. Immunology 1999, 21(2):129-135.
  • Penichet, M., Shin, S.-U. and Morrison, S. L. Fab Fusion Proteins: Immunoligands, In Antibody Fusion Proteins (Eds. S. T. Chamow and A. Ashkenazi), 1999, 15-52.
  • Challita, P.-M., Penichet, M. L., Shin, S.-U., Mosammaparast, N., Poles, T. M., Mahmood, K., Slamon, D. S., Morrison, S. L. and Rosenblatt, J. D. A B7.1-Antibody Fusion Protein Retains Antibody Specificity and Ability to Activate via the T Cell Costimulatory Pathway. J. Immunol., 1998, 160(7):3419-3426.
  • Cho, M.-Y., Kim, H. J., Cho, H. M. and Shin, S.-U. Affinity improvement of antibody-avidin fusion protein for biotin. Korean J. Immunology 1998, 20(4):381-388
  • Shin, S.-U., Wu, D., Ramanathan, R., Pardridge, W. M. and Morrison, S. L. Functional and Pharmacokinetic Properties of Antibody/Avidin Fusion Proteins. J. Immunol., 1997, 158(10):4797-4804
  • Sensel, M. G., Coloma, M. J., Harvill E. T., Shin, S.-U., Smith, R. I. F. and Morrison, S. L. Engineering Novel Antibody Molecules. Chem. Immunol., 1997, 65:129-158.
  • Morrison, S.L. and Shin, S.-U. Genetically engineered antibodies and their application to brain delivery. Advanced Drug Delivery Reviews., 1995, 15(1-3):145-175.
  • Morrison, S. L., Coloma, M. J., Espinoza, D., Hastings, A., Shin, S.-U., Wims, L. A., and Wright, A. Vectors and Approaches for the Eukaryotic Expression of Antibodies and Antibody Fusion Proteins: In Antibody Engineering 2nd Edition. (Ed. Borresbaeck, C. A. K.), 1995, pp267-293.
  • Shin, S.-U., Friden, P. M., Moran, M., Olson, T., Kang, Y.-S, Pardridge, W. M. and Morrison, S. L. Transferrin/Antibody Fusion Proteins Are Effective In Brain Targeting. Proc. Natl. Acad. Sci. U.S.A., 1995, 92(7):2820-4.
  • Shin, S.-U., Friden, P. M., Moran, M., and Morrison, S. L. Functional properties of antibody insulin-like growth factor fusion proteins. J. Biol. Chem., 1994, 269(7):4979-85.
  • Shin, S.-U., Wright, A., and Morrison, S.L. Hybrid Antibodies. Intern. Rev. Immunol., 1993, 10:177-186.
  • Shin, S.-U., Wright, A., Bonagura, V., and Morrison, S.L. Genetically engineered antibodies: Tools for the study of diverse properties of the antibody molecule. Immunol. Rev.,1992, 130:87-107.
  • Wright, A., Shin, S.-U., and Morrison, S.L. Recombinant antibodies. Critical Rev. Immunol., 1992, 12:125-168
  • Shin, S.-U., Wei, C.-F., Amin, A.R., Thornbecke, G.J., and Morrison, S.L. Structural and functional properties of mouse/human chimeric IgD. Human Antibodies and Hybridomas., 1992, 3: 65-74.
  • Wright, A and Shin, S.-U. Production of genetically engineered antibodies in myeloma cells:design, expression, and application. Methods: A Companion to Methods in Enzymology, 1991, 2(2):125-135.
  • Shin, S.-U., DePinho, R. A., Zack, D.J., and Scharff, M. D. Instability of immunoglobulin genes in S107 cell line. Somatic Cell and Molecular Genetics, 1991, 17 (3):259-76.
  • Shin, S.-U. and Morrison, S. L. Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: potential application for cellular targeting, Proc. Natl. Acad. Sci. U.S.A., 1990, 87(14):5322-26.
  • Shin, S.-U. and Morrison, S. L. Production and properties of chimeric antibody molecules. Methods in Enzymology, 1989, 178:459-476.
  • Behar, S. M., Chien, N. C., Corbet, S., Diamond, B., Getzoff, ED., Lustgarten, D., Roberts, V. A., Scharff, M. D., and Shin, S.-U. Impact of somatic mutation on the S107(T15) heavy-chain V region of antibodies reactive with self and nonself. Cold Spring Harbor Sym. Quan. Biol.. 1989, 54 Pt 2:921-31.
  • Scharff, M. D., Aguila, H. L., Behar, S., Chien, N., DePinho, R., French, D., Pollock, R. R., and Shin, S.-U. Studies on the somatic instability of immunoglobulin genes in vivo and in cultured cells. Immunol. Revs., 1989, 96:75-90.
  • Giusti, A. M., Chien, N., Zack, D. J., Shin, S.-U., and Scharff, M. D. The somatic diversification of S107 from an anti-PC to an anti-DNA autoantibody is due to a single base change in its heavy chain variable region. Proc. Natl. Acad. Sci. U.S.A., 1987, 84:2926-2930.
  • Scharff, M. D., DePinho, R. A., Behar, S., Beychok, C., Shin, S.-U., and French, D. The role of monoclonal antibodies and the recombinant DNA technology in studying autoantibody production. Cell Imunol., 1986, 99:29-37.
  • Chien, N., Guisti, A. M., Zack, D., French, D., Shin, S.-U., Diamond, B., and Scharff, M. D. Effect of somatic mutation on antibody affinity and specificity. Mt. Sinai J. Med., 1986, 53:181-186.
  • Inturrisi, C. E., Max, M. B., Foley, K. M., Schultz, M., Shin, S.-U., and Houde, R. W. The pharmacokinetics of heroin in patients with chronic pain. N. Engl. J. Med., 1984, 310:1213-1217
  • Inturrisi, C. E., Schultz, M., Shin, S.-U., Umans, J. G., Angel, L., and Simon, E. J. Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci., 1983, 33 (Suppl. II):773-776.
  • Umans, J. G., Chiu, T. S. K., Lipman, R. A., Schultz, M. F., Shin, S.-U., and Inturrisi, C. E. Determination of heroin and its metabolites by high-performance liquid chromatography. J. Chromatogr., 1982, 233:213-225.